Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Combination Pinometostat and 5-Azacitidine for the Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia, or Newly Diagnosed Patients Who Are Ineligible for or Unwilling to Undergo Intensive Therapy, Who Harbor an 11q23 Rearrangement

Trial Profile

Combination Pinometostat and 5-Azacitidine for the Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia, or Newly Diagnosed Patients Who Are Ineligible for or Unwilling to Undergo Intensive Therapy, Who Harbor an 11q23 Rearrangement

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Dec 2018

At a glance

  • Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Pinometostat (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Nov 2018 Planned initiation date changed from 16 Nov 2018 to 16 Jan 2019.
    • 18 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top